381 related articles for article (PubMed ID: 34625124)
1. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion.
Qiu Y; Chen T; Hu R; Zhu R; Li C; Ruan Y; Xie X; Li Y
Biomark Res; 2021 Oct; 9(1):72. PubMed ID: 34625124
[TBL] [Abstract][Full Text] [Related]
2. Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.
Martinez-Bosch N; Vinaixa J; Navarro P
Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29301364
[TBL] [Abstract][Full Text] [Related]
3. Blockade of DC-SIGN
Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
5. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract][Full Text] [Related]
6. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
8. Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development.
Wei Q; Taskén K
Biochem J; 2022 Oct; 479(20):2219-2260. PubMed ID: 36305711
[TBL] [Abstract][Full Text] [Related]
9. The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy.
Ge Z; Ding S
Front Oncol; 2020; 10():590941. PubMed ID: 33224886
[TBL] [Abstract][Full Text] [Related]
10. Targeting tumor-associated macrophages as an antitumor strategy.
Cheng N; Bai X; Shu Y; Ahmad O; Shen P
Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
[TBL] [Abstract][Full Text] [Related]
11. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.
Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS
ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260
[TBL] [Abstract][Full Text] [Related]
12. Targeting tumor-associated macrophages in the tumor microenvironment.
Zhou K; Cheng T; Zhan J; Peng X; Zhang Y; Wen J; Chen X; Ying M
Oncol Lett; 2020 Nov; 20(5):234. PubMed ID: 32968456
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy.
Zhang SY; Song XY; Li Y; Ye LL; Zhou Q; Yang WB
Pharmacol Res; 2020 Nov; 161():105111. PubMed ID: 33065284
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy.
Zhao YD; Muhetaerjiang M; An HW; Fang X; Zhao Y; Wang H
Biomaterials; 2021 Jan; 268():120552. PubMed ID: 33307365
[TBL] [Abstract][Full Text] [Related]
15. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive cells in tumor immune escape and metastasis.
Liu Y; Cao X
J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment.
Wang J; Li D; Cang H; Guo B
Cancer Med; 2019 Aug; 8(10):4709-4721. PubMed ID: 31222971
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages: implications in cancer immunotherapy.
Petty AJ; Yang Y
Immunotherapy; 2017 Mar; 9(3):289-302. PubMed ID: 28231720
[TBL] [Abstract][Full Text] [Related]
19. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
Fujimura T; Aiba S
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
[TBL] [Abstract][Full Text] [Related]
20. Pi (Spleen)-deficiency syndrome in tumor microenvironment is the pivotal pathogenesis of colorectal cancer immune escape.
Sun XG; Lin XC; Diao JX; Yu ZL; Li K
Chin J Integr Med; 2016 Oct; 22(10):789-94. PubMed ID: 26556710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
